Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MVA-BN-Filo and Ad26.ZEBOV Prime-Boost Regimens in Healthy Adults
NCT02313077Phase 1Completed
- Sponsor
- Crucell
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zabdeno and Mvabea in Ebola virus disease (EVD) (5 arms), sponsored by Crucell. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events at Day 360 and 1 more. Started Dec 2014; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02313077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313077.